Francois Brisebois
Stock Analyst at Oppenheimer
(2.36)
# 2,557
Out of 5,124 analysts
87
Total ratings
41.38%
Success rate
1.15%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $6.46 | +23.84% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $6.03 | -0.50% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $10.67 | +649.77% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $5.27 | +203.61% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $1.63 | +145.40% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $81.88 | -12.07% | 7 | Jan 22, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $37.42 | +63.01% | 6 | Jan 13, 2025 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $13.39 | +49.37% | 4 | Dec 17, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $10.28 | +172.37% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $21.55 | +39.21% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $143 → $163 | $294.74 | -44.70% | 4 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $19.56 | +181.19% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.56 | +2,598.33% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $7.96 | -24.62% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.97 | +121.33% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $25.01 | -44.02% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $18.23 | +256.56% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $5.18 | +93.05% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $8.18 | +1,758.19% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $18.46 | +95.02% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $2,500 → $1,500 | $2.88 | +51,983.33% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $1.53 | +352,841.18% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $2.95 | +272.88% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $3.57 | +404.20% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $6.90 | +624.64% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $0.75 | +431,612.19% | 1 | Feb 4, 2020 |
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $6.46
Upside: +23.84%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $6.03
Upside: -0.50%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $10.67
Upside: +649.77%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $5.27
Upside: +203.61%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $1.63
Upside: +145.40%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $81.88
Upside: -12.07%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $37.42
Upside: +63.01%
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $13.39
Upside: +49.37%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $10.28
Upside: +172.37%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $21.55
Upside: +39.21%
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $294.74
Upside: -44.70%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $19.56
Upside: +181.19%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $0.56
Upside: +2,598.33%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $7.96
Upside: -24.62%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.97
Upside: +121.33%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $25.01
Upside: -44.02%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $18.23
Upside: +256.56%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $5.18
Upside: +93.05%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $8.18
Upside: +1,758.19%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $18.46
Upside: +95.02%
Apr 3, 2023
Maintains: Outperform
Price Target: $2,500 → $1,500
Current: $2.88
Upside: +51,983.33%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $1.53
Upside: +352,841.18%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $2.95
Upside: +272.88%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $3.57
Upside: +404.20%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $6.90
Upside: +624.64%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $0.75
Upside: +431,612.19%